Clinical Trial Update: An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 open-label study of bavituximab plus pembrolizumab in advanced gastric and gastroesophageal junction cancer has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: OncXerna Theraputics, Inc. | Conditions: Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-02-08